Suche klinische Studie
Weitere Suchoptionen
275 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
PREDICT: Antibakterielle Prophylaxe und Nierenparenchymschäden bei angeborenen Fehlbildungen der Nieren und ableitenden Harnwege
Zentrum für Kinder- und Jugendmedizin - Angelika-Lautenschläger-Klinik
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304 - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de neurologie pédiatrique
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EXIST-LT: Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301- BE
Universitair Ziekenhuis Brussel
Pediatric neurology / Neurologie Kinderen
BELGIEN
VLAAMS BRABANT
LEUVEN
CORAL study: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children - BE
UZ Leuven - Campus Gasthuisberg
Referentiecentrum voor kindernefrologie
BELGIEN
VLAAMS BRABANT
LEUVEN
Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria - BE
UZ Leuven - Campus Gasthuisberg
Referentiecentrum voor kindernefrologie
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Effectiveness and safety of mTOR-inhibitor in patients with tuberous sclerosis complex-KD
Universitätsklinikum Heidelberg
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-3: A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures (Phase III) - FR
Institution: Information not provided - FR
FRANKREICH
ILE-DE-FRANCE
PARIS
MAGMAT : Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial (Phase III)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service de réanimation médicale
FRANKREICH
NORMANDIE
ROUEN
ITALIEN
LAZIO
ROMA
Medical treatment of cystinuria
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
Dipartimento di Nefrologia e Urologia
NIEDERLANDE
Zuid-Holland
ROTTERDAM
RATE trial: Randomised open label cross-over study into the efficacy of rapamycin in children with Tuberous Sclerosis Complex with intractable epilepsy (phase II/III trial)
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NIEDERLANDE
Zuid-Holland
ROTTERDAM
RAPIT trial: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (phase II/III trial)
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
STAGED-PKD: Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Phase II-III) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study (Phase 3)
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.-GB
Institution: Information not provided - CH
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria (Phase III) - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
STAGED-PKD: Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
An exploratory, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered GLPG2737 for 52 weeks, in subjects with autosomal dominant polycystic kidney disease - ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
Setmelanotide (RM-493): Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
SPANIEN
Madrid
MADRID
A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and AlstrC6m syndrome (AS) Patients with Moderate to Severe Obesity - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
VEREINIGTE STAATEN
Indiana
INDIANAPOLIS
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney (Phase II) - US
Indiana University School of Medicine
VEREINIGTE STAATEN
Minnesota
ROCHESTER
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children-GB
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria-GB
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
West Midlands
BIRMINGHAM
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy - BE
Erasme Hospital - ULB
Néphrologie
BELGIEN
VLAAMS BRABANT
LEUVEN
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - BE
UZ Leuven - Campus Gasthuisberg
Department of Human Genetics
DEUTSCHLAND
Bayern
MÜNCHEN
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
LMU Klinikum der Universität München - Campus Großhadern
LMU Klinikum
DEUTSCHLAND
Bayern
MÜNCHEN
SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
TUM Fakultät für Medizin
DEUTSCHLAND
Bayern
MÜNCHEN
SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
kbo-Kinderzentrum München gemeinnützige GmbH
kbo-Kinderzentrum München
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
ACCOLADE: Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Untersuchung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie
Institution: Information not provided - DE
DEUTSCHLAND
Niedersachsen
GÖTTINGEN
EARLY PRO-TECT Alport: Prospektive, randomisierte, Placebo-kontrollierte, doppelblinde, Industrie-unabhängige, multizentrische Studie mit ACE-Hemmer Ramipril versus Placebo bei frühen Stadien des Alport Syndroms: optimaler Therapiestart und Sicherheit (Phase III)
Universitätsmedizin Göttingen
Klinik für Nephrologie und Rheumatologie
DEUTSCHLAND
Niedersachsen
HANNOVER
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)
DEUTSCHLAND
Nordrhein-Westfalen
BONN
EyNeP: Intravitreales Aflibercept (Eylea®) zur Therapie von choroidalen Neovaskularisationen und fibrovaskulären Proliferationen in Patienten mit Pseudoxanthoma elasticum (Phase II)
Universitäts-Augenklinik Bonn
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
Universitätsklinikum Essen
DEUTSCHLAND
Sachsen
DRESDEN
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
DEUTSCHLAND
Schleswig-Holstein
LÜBECK
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A multicentre, open-label, extension study, evaluating the safety and tolerability and the efficacy of ADV7103 at long term in distal renal tubular acidosis patients (Phase III) - FR
Institution: Information not provided - FR
FRANKREICH
PAYS DE LA LOIRE
NANTES
Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 - FR
CHU de Nantes
CHU Nantes
FRANKREICH
PAYS DE LA LOIRE
NANTES
STOPECU : Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS) (Phase IV)
CHU de Nantes - Hôtel Dieu
Service de néphrologie et immunologie clinique
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Evaluation of clinical response to rituximab treatment in patients with acquired autoimmune recurrent thrombotic thrombocytopenic purpura (TTP) - RTXTTP2010
Institution: Information not provided - IT
ITALIEN
LOMBARDIA
MILANO
An open-label, multi-center clinical trial of eculizumab in pediatric patients with atypical hemolytic-uremic syndrome (aHUS) (Phase II) - IT
IRCCS Ca' Granda Ospedale Maggiore Policlinico - Padiglione De Marchi
Centro per la Cura e lo Studio della Sindrome Emolitico Uremica (Center for HUS Control)
NIEDERLANDE
Gelderland
NIJMEGEN
An open-label, multi-center clinical trial of eculizumab in pediatric patients with atypical hemolytic-uremic syndrome (aHUS) (Phase II) - NL
Radboudumc - Radboud universitair medisch centrum
Afdeling Kindernefrologie
NIEDERLANDE
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NIEDERLANDE
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Neurowetenschappen
NIEDERLANDE
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - BE
Erasmus MC - Erasmus Medisch Centrum
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
Post-HERCULES: Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Phase III) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2-period Crossover Study With a Single Arm Continuation Evaluating the Safety and Efficacy of BAX 930 (rADAMTS13) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS-13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Nephrologie und Gastroenterologie
OSTERREICH
WIEN
WIEN
SPANIEN
Andalucía
CÓRDOBA
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Hospital Universitario Reina Sofía
Unidad de Pediatría
SPANIEN
Andalucía
MÁLAGA
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) (Phase III) - ES
Hospital Regional Universitario de Málaga - Hospital General
Servicio de Nefrología
SPANIEN
Andalucía
MÁLAGA
Response to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) (Phase II) - ES
Hospital Universitario Virgen de la Victoria
Unidad de Medicina Interna
SPANIEN
Andalucía
SEVILLA
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Hospital Universitario Virgen del Rocío
Unidad de Pediatría
SPANIEN
Cataluña
BADALONA
OPTIMAB: Pilot study for the optimitzation of the maintenance dose of eculizumab according to the weight in adult patients with atypic hemolytic uremic syndrome (Phase IV) - ES
Hospital Germans Trias I Pujol
SPANIEN
Cataluña
BARCELONA
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) (Phase III) - ES
Hospital Clínic de Barcelona
Instituto Clínic de Nefrología y Urología
SPANIEN
Cataluña
BARCELONA
OPTIMAB: Pilot study for the optimitzation of the maintenance dose of eculizumab according to the weight in adult patients with atypic hemolytic uremic syndrome (Phase IV) - ES
Hospital Universitari Vall d'Hebron
SPANIEN
Cataluña
BARCELONA
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy - ES
Hospital Universitari Vall d'Hebron
Servicio de Nefrología
SPANIEN
Cataluña
BARCELONA
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) (Phase III) - ES
Hospital Universitari Vall d'Hebron
Servicio de Nefrología
SPANIEN
Cataluña
BARCELONA
An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy (Phase II) - ES
Hospital Universitari Vall d'Hebron
Servicio de Nefrología
SPANIEN
Cataluña
BARCELONA
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Hospital Universitari Vall d'Hebron
Servicio de Pediatría
SPANIEN
Cataluña
ESPLUGUES DE LLOBREGAT
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Hospital Sant Joan de Déu Barcelona
Servicio de Nefrología
SPANIEN
Cataluña
GIRONA
OPTIMAB: Pilot study for the optimitzation of the maintenance dose of eculizumab according to the weight in adult patients with atypic hemolytic uremic syndrome (Phase IV) - ES
Hospital Universitari de Girona Dr. Josep Trueta
SPANIEN
Cataluña
L'HOSPITALET DE LLOBREGAT
OPTIMAB: Pilot study for the optimitzation of the maintenance dose of eculizumab according to the weight in adult patients with atypic hemolytic uremic syndrome (Phase IV) - ES
Hospital Universitari de Bellvitge
SPANIEN
Cataluña
L'HOSPITALET DE LLOBREGAT
An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy (Phase II) - ES
Hospital Universitari de Bellvitge
Servicio de Nefrología
SPANIEN
Cataluña
LÉRIDA
OPTIMAB: Pilot study for the optimitzation of the maintenance dose of eculizumab according to the weight in adult patients with atypic hemolytic uremic syndrome (Phase IV) - ES
Hospital Universitario Arnau de Vilanova
SPANIEN
Cataluña
TARRAGONA
OPTIMAB: Pilot study for the optimitzation of the maintenance dose of eculizumab according to the weight in adult patients with atypic hemolytic uremic syndrome (Phase IV) - ES
Hospital Universitari de Tarragona Joan XXIII
SPANIEN
Comunidad Valenciana
VALENCIA
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) (Phase III) - ES
Hospital Universitario Doctor Peset
Servicio de Nefrología
SPANIEN
Comunidad Valenciana
VALENCIA
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) (Phase III) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Nefrología
SPANIEN
Comunidad Valenciana
VALENCIA
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Pediatría
SPANIEN
Galicia
BURELA
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy - ES
Hospital da Costa - Burela
Servicio de Nefrología
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2-period Crossover Study With a Single Arm Continuation Evaluating the Safety and Efficacy of BAX 930 (rADAMTS13) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
An open-label, non-randomized study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
SOAR-HI: A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
HERA: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome - ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) (Phase III) - ES
Hospital Clínico San Carlos
Servicio de Nefrología
SPANIEN
Madrid
MADRID
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy - ES
Hospital Universitario 12 de Octubre
Servicio de Nefrología
SPANIEN
Madrid
MADRID
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) (Phase III) - ES
Hospital Universitario 12 de Octubre
Servicio de Nefrología
SPANIEN
Madrid
MADRID
An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy (Phase II) - ES
Hospital Universitario 12 de Octubre
Servicio de Nefrología
SPANIEN
Madrid
MADRID
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Hospital Universitario La Paz
Servicio de Pediatría
VEREINIGTES KONIGREICH
Greater London
LONDON
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -GB
St Bartholomew's Hospital, Barts and The London NHS Trust
Barts & The London NHS Trust
VEREINIGTES KONIGREICH
Tyne & Wear
NEWCASTLE UPON TYNE
Multicentre, open label, prospective, single arm study of the safety and impact of Eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome
Institute of Cellular Medicine, Newcastle University, Medical School
Institute of Cellular Medicine
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VAIN study: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome - BE
Universitair Ziekenhuis Brussel
Nefrologie dienst / Nephrology department
BELGIEN
OOST-VLAANDEREN
GENT
SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE
Ghent University Hospital - UZ Gent
Department of Rheumatology
DEUTSCHLAND
Baden-Württemberg
FREIBURG
ABASARC: Sicherheit und Wirksamkeit von Abatacept bei Patienten mit behandlungsresistenter Sarkoidose
Klinik für Pneumologie am Universitätsklinikum Freiburg
Klinik für Pneumologie
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Die VITAL-Amyloidose-Studie: Eine randomisierte, multizentrische, doppelblinde, Placebo-kontrollierte, 2-armige Phase 3-Studie zur Untersuchung der Wirksamkeit und Sicherheit von NEOD001 plus Standardtherapie im Vergleich zu Placebo plus Standardtherapie bei Patienten mit Leichtketten- (AL-) Amyloidose
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Eine randomisierte, kontrollierte, offene, multizentrische Phase III-Studie zur Untersuchung der Sicherheit und Wirksamkeit von Dexamethason plus MLN9708 im Vergleich zur Therapie nach Wahl des Arztes bei Patienten mit rezidivierender oder refraktärer systemischer Leichtketten- (AL-) Amyloidose
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Eine randomisierte, multizentrische Phase III-Studie zum Vergleich einer Behandlung mit Melphalan und Dexamethason und mit Bortezomib-Melphalan-Dexamethason bei unbehandelten Patienten mit systemischer Leichtketten(AL)-Amyloidose
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Eine offene Phase-1/2-Studie von Melflufen und Dexamethason für Patienten mit Al-Amyloidose nach mindestens einer vorherigen Therapielinie
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
INTENT-Studie: Randomisierte, kontrollierte, multizentrische Therapiestudie zur Initialtherapie der Erstmanifestation des idiopathischen nephrotischen Syndroms im Kindesalter mit Mycophenolatmofetil versus Prednison
Zentrum für Kinder- und Jugendmedizin - Angelika-Lautenschläger-Klinik
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
TOFFIFE: Tocilizumab zur Behandlung des Familiären Mittelmeerfiebers - Eine randomisierte, doppelblinde Phase II Studie
Interdisziplinäres Rheumazentrum (INDIRA)
Zentrum für Interdisziplinäre Rheumatologie, klinische Immunologie und Autoimmunerkrankungen
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
PRESIDIO: Eine randomisierte, doppelblinde, placebokontrollierte Crossover multizentrische Phase 2-Studie zur Bewertung der Sicherheit und Wirksamkeit von KZR-616 bei der Behandlung von Patienten mit aktiver Polymyositis oder Dermatomyositis
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
BERLIN
CONSIDER: Eine multizentrische, Placebo-kontrollierte Phase II-Studie mit Canakinumab zur Behandlung des Adulten Still-Syndroms
Charité - Universitätsmedizin Berlin (CCM)
Autoinflammation Reference Center Charité (ARC²)
DEUTSCHLAND
Niedersachsen
HANNOVER
SENSCIS (TM) Extension: Eine offene Verlängerungsstudie zur Beurteilung der Langzeitsicherheit von Nintedanib bei Patienten mit Systemischer Sklerose assoziierter Interstitieller Lungenerkrankung (SSc-ILD).
Medizinische Hochschule Hannover
Klinik für Pneumologie
DEUTSCHLAND
Sachsen-Anhalt
DESSAU
Eine Phase 3, multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte, Parallelgruppen-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Apremilast (CC-10004) bei Patienten mit aktiver Behcet-Krankheit
Städtisches Klinikum Dessau
Klinik für Dermatologie, Venerologie und Allergologie / Immunologisches Zentrum
FINNLAND
Finland
TURKU
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI-
Turku University Hospital
Turku PET CENTRE
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR
Institution: Information not provided - FR
FRANKREICH
ILE-DE-FRANCE
PARIS
ITAC: Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease.
APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière
Département de Médecine Interne et Immunologie Clinique (DMIIC)
FRANKREICH
ILE-DE-FRANCE
PARIS
NEPHROMYCY - Cyclophosphamide versus mycophenolate mofetil for children with steroid-dependent idiopathic nephrotic syndrome : a multicenter randomized controlled trial (Phase III).
CHU Paris - Hôpital Robert Debré
Service de Néphrologie - Hémodialyse
FRANKREICH
ILE-DE-FRANCE
PARIS
NEPHROVIR3 : A Multicenter, Randomised, Double-blind Placebo-controlled Trial Assessing the Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children (Phase III)
CHU Paris - Hôpital Robert Debré
Service de Néphrologie - Hémodialyse
FRANKREICH
ILE-DE-FRANCE
PARIS
MSC: Treatment of Refractory Severe Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells - (Phase I-II) - FR
CHU Paris Centre - Hôpital Cochin, Site Cochin
Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire
FRANKREICH
NOUVELLE AQUITAINE
LIMOGES
AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR
CHU de Limoges - Hôpital Dupuytren
Service d'hématologie clinique et de thérapie cellulaire
FRANKREICH
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
SCLERADEC III : SCLERoderma and Adipose-DErived Stroma Cells (Phase II)
CHU de Marseille - Hôpital Nord
Service de Médecine Interne
IRLAND
County Dublin
DUBLIN
A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy - IE
Beaumont Hospital
Kidney Centre
IRLAND
County Dublin
DUBLIN
SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE
St. Vincent's University Hospital
CF Clinic
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III)
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
OFA3: Efficacy of humanized anti-CD20 antibodies (Ofatumumab) in the treatment of childhood steroid-dependent nephrotic syndrome and development of cell biomarkers predicting outcome
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy - IT
Institution: Information not provided - IT
ITALIEN
LAZIO
ROMA
Efficacy of monoclonal anti CD 20 antibodies in steroid and cyclosporin dependent nephrotic syndrome in children - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE SAN PAOLO
Laboratorio di Nefrologia - Divisione di Nefrologia e Dialisi
ITALIEN
LIGURIA
GENOVA
Five-year actively controlled clinical trial in new onset juvenile dermatomyositis
IRCCS Istituto G. Gaslini - Ospedale Pediatrico
U.O. Pediatria II
ITALIEN
LOMBARDIA
PAVIA
A randomized open-label multicenter phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis - IT
Fondazione IRCCS Policlinico San Matteo
Laboratorio di Biotecnologie e Tecnologie Biomediche
ITALIEN
LOMBARDIA
PAVIA
A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - IT
Fondazione IRCCS Policlinico San Matteo
Dipartimento di Medicina Molecolare
ITALIEN
TOSCANA
FIRENZE
ASTIS: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis (Phase III) - IT
AOU Careggi
Dipartimento di Biomedicina
ITALIEN
TOSCANA
FIRENZE
Randomized Controlled Trial for Testing the Efficacy of Well-Being Therapy in Patients With Systemic Sclerosis
Università degli studi di Firenze
Dipartimento di Scienze della Salute
NIEDERLANDE
Gelderland
NIJMEGEN
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone
Radboudumc - Radboud universitair medisch centrum
Afdeling Nierziekten
NIEDERLANDE
Noord-Holland
AMSTERDAM
Levamisole treatment for children with steroid sensitive nephrotic syndrome. An international multi-centre, double-blind, placebo-controlled, randomised trial
Amsterdam UMC, locatie AMC
Polikliniek Kindernefrologie
NIEDERLANDE
Noord-Holland
AMSTERDAM
IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study
Amsterdam UMC, locatie AMC
Afdeling Neurologie
NIEDERLANDE
Utrecht
UTRECHT
The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II)
UMC Utrecht - Universitair Medisch Centrum Utrecht
Afdeling Nefrologie
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD) (Phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2)
Institution: Information not provided - AT
PORTUGAL
CENTRO
ADDRESS: NOT PROVIDED - PT
EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - PT
Institution: Information not provided - PT
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - CH
Institution: Information not provided - CH
SPANIEN
Cataluña
BARCELONA
A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis - ES
Hospital Clínic de Barcelona
Servicio de Hematología
SPANIEN
Cataluña
BARCELONA
An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - ES
Hospital Clínic de Barcelona
Servicio de Hematología
SPANIEN
Cataluña
BARCELONA
ReDox: A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ES
Hospital Clínic de Barcelona
Servicio de Hematología
SPANIEN
Cataluña
BARCELONA
An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitari Vall d'Hebron
Servicio de Medicina Interna
SPANIEN
Cataluña
BARCELONA
DETERMINE: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis - ES
Hospital Universitari Vall d'Hebron
Servicio de Medicina Interna
SPANIEN
Cataluña
BARCELONA
An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Medicina Interna
SPANIEN
Comunidad Valenciana
VALENCIA
An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario Doctor Peset
SPANIEN
Comunidad Valenciana
VALENCIA
An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario y Politécnico La Fe
SPANIEN
Galicia
VIGO
An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Álvaro Cunqueiro
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
RECLAIIM: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis - ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital General Universitario Gregorio Marañón
SPANIEN
Madrid
MADRID
An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario 12 de Octubre
TUNESIEN
TUNISIA
ADDRESS: NOT PROVIDED - TN
EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - TN
Institution: Information not provided - TN
TURKEI
TURKEY
ADDRESS: NOT PROVIDED - TR
EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - TR
Institution: Information not provided - TR
UNGARN
Közép-Magyarország
BUDAPEST
A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Institute of Genomic Medicine and Rare Disorders, Semmelweis University
Genetics Laboratory
VEREINIGTE STAATEN
Maryland
BALTIMORE
Study of Growth Hormone Use in Patients With Pseudohypoparathyroidism Type 1a (Subtype of Albright Hereditary Osteodystrophy) (Phase 2/3) - US
Kennedy Krieger Institute
VEREINIGTE STAATEN
Pennsylvania
PHILADELPHIA
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis - US
University of Pennsylvania
Perelman School of Medicine
VEREINIGTE STAATEN
Washington
SEATTLE
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
University of Washington
VEREINIGTES KONIGREICH
Cardiff
CARDIFF
Developing a non-invasive treatment for twin-twin transfusion syndrome
Centre for Trials Research
VEREINIGTES KONIGREICH
Greater London
LONDON
Developing a non-invasive treatment for twin-twin transfusion syndrome
Imperial College London
Institute of Reproductive and Developmental Biology
VEREINIGTES KONIGREICH
Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)GB
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
SALFORD
Cold Challenge With C21 in RP
Salford Royal NHS Foundation Trust
University of Manchester Rheumatic Diseases Centre
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis - BE
Institution: Information not provided - BE
BELGIEN
LIEGE
LIEGE
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis (Phase II) - BE
CHU Sart Tilman - Liège
CHU de Liège (ULG)
BELGIEN
OOST-VLAANDEREN
GENT
NOVESA study: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis - BE
Ghent University Hospital - UZ Gent
Department of Rheumatology
BELGIEN
VLAAMS BRABANT
LEUVEN
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
UZ Leuven - Campus Gasthuisberg
UZ Leuven
DEUTSCHLAND
Baden-Württemberg
FREIBURG
Eine randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Studie zur Beurteilung der Sicherheit und Wirksamkeit einer Behandlung mit Branebrutinib bei Teilnehmern mit aktivem systemischem Lupus erythematodes oder primärem Sjögren-Syndrom oder einer Behandlung mit Branebrutinib, gefolgt von einer offenen Behandlung mit Abatacept bei Teilnehmern mit aktiver rheumatoider Arthritis
Universitätsklinikum Freiburg
Klinik für Rheumatologie und Klinische Immunologie
DEUTSCHLAND
Baden-Württemberg
FREIBURG
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Freiburg
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Heidelberg
DEUTSCHLAND
Baden-Württemberg
MANNHEIM
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsmedizin Mannheim
Universitätsklinikum Mannheim
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
AST-MOMA: Hochdosis-Chemotherapie und Transplantation von CD34-selektionierten Stammzellen bei progressiver systemischer Sklerose - Modifikation nach Manifestation (Phase II)
Interdisziplinäres Rheumazentrum (INDIRA)
Zentrum für Interdisziplinäre Rheumatologie, klinische Immunologie und Autoimmunerkrankungen
DEUTSCHLAND
Baden-Württemberg
ULM
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Ulm
DEUTSCHLAND
Bayern
ERLANGEN
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Internistisches Zentrum des Universitätsklinikums Erlangen
Medizinische Klinik 3 - Rheumatologie und Immunologie
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Mepolizumab Langzeitzugangsprogramm für Probanden, die an der Studie MEA115921 (Placebo-kontrollierte Studie von Mepolizumab zur Behandlung von eosinophiler Granulomatose mit Polyangiitis bei Probanden mit Standardtherapie) teilgenommen haben. - DE-
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
BERLIN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Charité - Universitätsmedizin Berlin
DEUTSCHLAND
Berlin
BERLIN
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Charité - Universitätsmedizin Berlin (CCM)
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie
DEUTSCHLAND
Berlin
BERLIN
Eine randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Studie zur Beurteilung der Sicherheit und Wirksamkeit einer Behandlung mit Branebrutinib bei Teilnehmern mit aktivem systemischem Lupus erythematodes oder primärem Sjögren-Syndrom oder einer Behandlung mit Branebrutinib, gefolgt von einer offenen Behandlung mit Abatacept bei Teilnehmern mit aktiver rheumatoider Arthritis
Charité - Universitätsmedizin Berlin (CCM)
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie
DEUTSCHLAND
Hamburg
HAMBURG
Eine multizentrische, offene Studie zur Untersuchung der Pharmakokinetik, Sicherheit und Pharmakodynamik von subkutan verabreichtem Belimumab, einem humanen monoklonalen Anti-BLyS-Antikörper, plus Standardtherapie bei pädiatrischen Teilnehmern mit systemischem Lupus erythematodes (SLE) (Phase II)
Schön Klinik Hamburg Eilbek
Hamburger Zentrum für Kinder- und Jugendrheumatologie
DEUTSCHLAND
Hessen
BAD NAUHEIM
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Sicherheit und Wirksamkeit von BMS-986165 mit einer Hintergrundbehandlung bei Teilnehmern mit Lupus-Nephritis
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
DEUTSCHLAND
Niedersachsen
HANNOVER
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Sicherheit und Wirksamkeit von BMS-986165 mit einer Hintergrundbehandlung bei Teilnehmern mit Lupus-Nephritis
Medizinische Hochschule Hannover
Klinik für Nieren- und Hochdruckerkrankungen
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Essen
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Sicherheit und Wirksamkeit von BMS-986165 mit einer Hintergrundbehandlung bei Teilnehmern mit Lupus-Nephritis
Universitätsklinikum Essen
DEUTSCHLAND
Nordrhein-Westfalen
HERNE
Eine randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Studie zur Beurteilung der Sicherheit und Wirksamkeit einer Behandlung mit Branebrutinib bei Teilnehmern mit aktivem systemischem Lupus erythematodes oder primärem Sjögren-Syndrom oder einer Behandlung mit Branebrutinib, gefolgt von einer offenen Behandlung mit Abatacept bei Teilnehmern mit aktiver rheumatoider Arthritis
St. Josefs-Krankenhaus
Rheumazentrum Ruhrgebiet
DEUTSCHLAND
Nordrhein-Westfalen
KÖLN
Eine randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Studie zur Beurteilung der Sicherheit und Wirksamkeit einer Behandlung mit Branebrutinib bei Teilnehmern mit aktivem systemischem Lupus erythematodes oder primärem Sjögren-Syndrom oder einer Behandlung mit Branebrutinib, gefolgt von einer offenen Behandlung mit Abatacept bei Teilnehmern mit aktiver rheumatoider Arthritis
Universitätsklinikum Köln
Klinik I für Innere Medizin
DEUTSCHLAND
Nordrhein-Westfalen
KÖLN
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Köln
Klinik und Poliklinik für Dermatologie und Venerologie
DEUTSCHLAND
Nordrhein-Westfalen
MÜNSTER
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Münster
DEUTSCHLAND
Nordrhein-Westfalen
SANKT AUGUSTIN
Eine multizentrische, offene Studie zur Untersuchung der Pharmakokinetik, Sicherheit und Pharmakodynamik von subkutan verabreichtem Belimumab, einem humanen monoklonalen Anti-BLyS-Antikörper, plus Standardtherapie bei pädiatrischen Teilnehmern mit systemischem Lupus erythematodes (SLE) (Phase II)
Asklepios Kinderklinik Sankt Augustin GmbH
Abteilung für Allgemeine Kinder- und Jugendmedizin
DEUTSCHLAND
Rheinland-Pfalz
MAINZ
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Sicherheit und Wirksamkeit von BMS-986165 mit einer Hintergrundbehandlung bei Teilnehmern mit Lupus-Nephritis
Universitätsmedizin Mainz
DEUTSCHLAND
Sachsen
DRESDEN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
DEUTSCHLAND
Thüringen
JENA
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
MAINEPSAN Study: A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of Prednisone in Systemic anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis
CHU de Lyon HCL - GH Sud
Service de médecine interne et pathologie vasculaire
FRANKREICH
BOURGOGNE-FRANCHE-COMTE
DIJON
METOGiA: MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
CHU Dijon Bourgogne - Hôpital François Mitterrand
Service de médecine interne et immunologie clinique
FRANKREICH
ILE-DE-FRANCE
ISSY-LES-MOULINEAUX
INTOReTAK: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis.
Hôpital Corentin-Celton
Service de Réadaptation vasculaire
FRANKREICH
ILE-DE-FRANCE
PARIS
MSC-LES: Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord
CHU Paris Centre - Hôpital Cochin, Site Cochin
Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire
FRANKREICH
ILE-DE-FRANCE
PARIS
CHUSPAN2 : Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Churg Strauss Syndrome Without Poor Prognosis Factors (Phase III)
CHU Paris Centre - Hôpital Cochin, Site Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
FRANKREICH
ILE-DE-FRANCE
PARIS
TOCITAKA : Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study (Phase III)
CHU Paris Est - Hôpital Saint-Antoine
Service de médecine interne
IRLAND
County Galway
GALWAY
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma - IE
University Hospital Galway
Department of Haematology
ITALIEN
PUGLIA
BARI
Combined Therapy With Peg-Interferon alpha, Ribavirin And Rituximab Of Hepatitis C Virus-Related Mixed Cryoglobulinemia - IT
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Unità di Epatologia - Sezione di Medicina Interna e Oncologia Clinica
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus - JP
Institution: Information not provided - JP
JAPAN
JAPAN
HYOGO
BRAVE II: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - JP
Eli Lilly Japan K.K.
NIEDERLANDE
Groningen
GRONINGEN
Prevention of Relapses in Proteinase 3 (PR3)-Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
UMCG - Universitair Medisch Centrum Groningen
Afdeling Nefrologie
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis (Phase 2) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
BRAVE I: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
SLE-BRAVE-X: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
SELECT-GCA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis (Phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
ARTEMIS-IGAN: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis (Phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
PHOENYCS GO: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (Phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse
POLEN
Warszawa
WARSAW
A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) In Subjects with Diffuse Cutaneous Systemic Sclerosis with Interstitial Lung Disease - PL
Instytut Reumatologii im. prof. dr hab. med. Eleonory Reicher
Klinika I Poliklinika Ukladowych Chorob Tkanki Lacznej
SCHWEIZ
Suisse Alémanique
BERN
GUSTO: Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab - CH
University Hospital Inselspital
Department of Rheumatology, Clinical Immunology Allergology
SPANIEN
Andalucía
MÁLAGA
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis (Phase II) - ES
Hospital Regional Universitario de Málaga - Hospital General
Unidad de Reumatología
SPANIEN
Andalucía
SEVILLA
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis (Phase II) - ES
Hospital Quirónsalud Infanta Luisa
Servicio de Reumatología
SPANIEN
Cataluña
BARCELONA
SPANIEN
Cataluña
BARCELONA
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis (Phase II) - ES
Hospital Universitari Vall d'Hebron
Servicio de Medicina Interna
SPANIEN
Cataluña
BARCELONA
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Medicina Interna
SPANIEN
Cataluña
ESPLUGUES DE LLOBREGAT
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) (Phase II) - ES
Hospital Sant Joan de Déu Barcelona
Unidad de Reumatología
SPANIEN
Comunidad Valenciana
VALENCIA
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis (Phase II) - ES
Hospital Clínico Universitario de Valencia
Servicio de Reumatología
SPANIEN
Comunidad Valenciana
VALENCIA
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis - ES
Hospital Universitario Doctor Peset
Servicio de Reumatología
SPANIEN
Comunidad Valenciana
VALENCIA
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) (Phase II) - ES
Hospital Universitario y Politécnico La Fe
Unidad de Reumatología Pediátrica
SPANIEN
Galicia
A CORUÑA
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis (Phase II) - ES
Hospital Universitario da Coruña
Servicio de Reumatología
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
PROTECT: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
NefIgArd: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients (Phase II) - ES
Hospital Clínico San Carlos
SPANIEN
Madrid
MADRID
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis - ES
Hospital General Universitario Gregorio Marañón
Servicio de Reumatología
SPANIEN
Madrid
MADRID
An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients (Phase II) - ES
Hospital Universitario 12 de Octubre
SPANIEN
Madrid
MADRID
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis - ES
Hospital Universitario 12 de Octubre
Servicio de Reumatología
SPANIEN
Madrid
MADRID
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis - ES
Hospital Universitario HM Sanchinarro
Servicio de Reumatología
SPANIEN
Madrid
MADRID
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) (Phase II) - ES
Hospital Universitario Ramón y Cajal
Servicio de Reumatología
SPANIEN
Madrid
SAN SEBASTIÁN DE LOS REYES
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis - ES
Hospital Universitario Infanta Sofía
Sección de Reumatología
VEREINIGTE STAATEN
Pennsylvania
PITTSBURGH
TAMER: The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis (Phase II) - US
University of Pittsburgh
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis-GB
Addenbrooke's Hospital
Addenbrookes Hospital
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
Addenbrooke's Hospital
Addenbrookes Hospital
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
Biologics in refractory vasculitis
University of Cambridge
Department of Medicine
VEREINIGTES KONIGREICH
Derbyshire
CHESTERFIELD
PRedSS:A Phase II Randomised Controlled Study of Oral Prednisolone in Early Diffuse Cutaneous Systemic Sclerosis -GB
Copeman House
Versus Arthritis (formerly Arthritis Research UK)
VEREINIGTES KONIGREICH
Greater London
LONDON
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis-GB
University College London Medical School and Royal Free Hospital
Metabolic Bone Disease - Centre for Rheumatology and Connective Tissue Diseases
VEREINIGTES KONIGREICH
Tayside
DUNDEE
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis-GB
Ninewells Hospital and Medical School
Multinationale klinische Studie(n)
SCHWEIZ
Suisse Alémanique
BASEL
EXIST-2: Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Novartis International AG
SCHWEIZ
Suisse Alémanique
BASEL
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.
Institution: Information not provided - CH
VEREINIGTE STAATEN
Massachusetts
CAMBRIDGE
BELGIEN
OOST-VLAANDEREN
ZWIJNAARDE
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A multicentre, open-label, extension study, evaluating the safety and tolerability and the efficacy of ADV7103 at long term in distal renal tubular acidosis patients.
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A multicentre, open-label, non-inferiority sequential study, evaluating the efficacy, safety, tolerability and acceptability of ADV7103 compared to standard of care in distal renal tubular acidosis patients.
Institution: Information not provided - FR
FRANKREICH
ILE-DE-FRANCE
LEVALLOIS-PERRET
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Europe SAS
VEREINIGTE STAATEN
Connecticut
CHESHIRE
An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) (coordination)
Alexion Pharmaceuticals, Inc.
VEREINIGTE STAATEN
Connecticut
CHESHIRE
An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) (coordination)
Alexion Pharmaceuticals, Inc.
VEREINIGTE STAATEN
Connecticut
CHESHIRE
An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) (coordination)
Alexion Pharmaceuticals, Inc.
VEREINIGTE STAATEN
Connecticut
CHESHIRE
An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) (coordination)
Alexion Pharmaceuticals, Inc.
VEREINIGTE STAATEN
Connecticut
CHESHIRE
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc.
VEREINIGTE STAATEN
Pennsylvania
WAYNE
SOAR-HI: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-blind Study in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) to Evaluate the Pharmacokinetics,Safety and Efficacy of rADAMTS-13 (SHP655) Administered in Addition to Standard Of Care (SoC) Treatment
Shire Development LLC and International Affiliates
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
SENSCIS : A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Institution: Information not provided - DE
IRLAND
County Dublin
ADDRESS: NOT PROVIDED - IE
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (Prematurely ended)
Institution: Information not provided - IE
ITALIEN
LOMBARDIA
PAVIA
A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
Fondazione IRCCS Policlinico San Matteo
Dipartimento di Medicina Molecolare
SCHWEDEN
Region Stockholm
STOCKHOLM
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy
Oncopeptides AB
SCHWEIZ
Suisse Alémanique
BASEL
TURKEI
TURKEY
ISTANBUL
EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) (TERMINATED)
Acibadem University
Department of ophtalmology
VEREINIGTE STAATEN
California
SOUTH SAN FRANCISCO
PRESIDIO: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomyositis
Kezar Life Sciences, Inc.
VEREINIGTE STAATEN
Maryland
GAITHERSBURG
VEREINIGTE STAATEN
Pennsylvania
PHILADELPHIA
An Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMF
Mutual Pharmaceutical Company, Inc.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
AMYDARA: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Greater London
LONDON
ASTIS: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous poulse therapy cyclophosphamide in severe systemic sclerosis (Phase III) (coordination) - terminated
Guy's Hospital
European Society for Blood and Marrow Transplant Society
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
Bristol Myers Squibb International Corporation
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Bristol Myers Squibb International Corporation
BELGIEN
VLAAMS BRABANT
MECHELEN
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
TERGISS : Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapyin Subjects With Diffuse Cutaneous Systemic Sclerosis
Institution: Information not provided - DE
DEUTSCHLAND
Nordrhein-Westfalen
LEVERKUSEN
DEUTSCHLAND
Thüringen
JENA
FRANKREICH
ILE-DE-FRANCE
PARIS
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Sanofi-aventis Groupe
SCHWEIZ
Suisse Alémanique
BASEL
FocuSSced study: A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
VEREINIGTE STAATEN
Connecticut
WALLINGFORD
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis
Bristol-Myers Squibb Company
Bristol-Myers Squibb
VEREINIGTE STAATEN
Illinois
NORTH CHICAGO
VEREINIGTE STAATEN
Indiana
INDIANAPOLIS
BRAVE II: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus
Eli Lilly and Company World Headquarters
VEREINIGTE STAATEN
Massachusetts
ROCKLAND
VEREINIGTE STAATEN
Michigan
ANN ARBOR
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
University of Michigan UH B1 H410/0028
University of Michigan
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Essex
HARLOW